Previous reports have mostly suggested that certain subsets of CD4+ TRM might be pro-inflammatory, whereas an altered population of CD8+ TRM might be immunosuppressive in the gut of IBD patients. This evidence concerns the gene CD8A and inflammatory bowel disease.